(Sofosbuvir + velpatasvir) is a Small Molecule owned by Gilead Sciences, and is involved in 77 clinical trials, of which 60 were completed, 15 are ongoing, and 2 are planned.

Sofosbuvir is an inhibitor of the HCV NS5B RNA-dependent RNA polymerase, which is essential for viral replication. Sofosbuvir is a nucleotide prodrug that undergoes intracellular metabolism to form the pharmacologically active uridine analog triphosphate which can be incorporated into HCV RNA by the NS5B polymerase and acts as a chain terminator. velpatasvir acts by inhibiting the pan-genotypic NS5A. NS5A functions through interaction with other viral and cellular proteins. By inhibiting NS5A, it retards cell growth and perturbs the cell cycle by targeting the Cdk1/2-cyclin complexes and other cell cycle control genes. Velpatasvir is an inhibitor of the HCV NS5A protein, which is required for viral replication.

The revenue for (Sofosbuvir + velpatasvir) is expected to reach a total of $10bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the (Sofosbuvir + velpatasvir) NPV Report.

(Sofosbuvir + velpatasvir) is currently owned by Gilead Sciences.

(Sofosbuvir + velpatasvir) Overview

Sofosbuvir and Velpatasivir (Epclusa) is a fixed dose combination drug, a nucleotide analog acts as anti-hepatitic agent. It is formulated as film coated tablets, tablets, granules and pellets for oral route of administration. Epclusa is indicated for the treatment of adult patients with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection. The hepatitis C virus (HCV) non-structural 5A (NS5A) protein is a pleiotropic protein with key roles in both viral RNA replication and modulation of the physiology of the host cell, and indicated for treatment of hepatitis C virus (HCV) in children ages 3 years and older or weighing at least 37 pounds (17 kilograms) with any of the six HCV genotypes or strains without cirrhosis (liver disease) or with compensated cirrhosis or with decompensated cirrhosis for use in combination with ribavirin.

The fixed dosed combination was under development for the treatment of chronic hepatitis C virus infection in treatment-naive and treatment-experienced pediatric patients.

Gilead Sciences Overview

Gilead Sciences (Gilead) is a research-based biopharmaceutical company. It is engaged in the discovery, development and commercialization of medicines for the treatment of cardiovascular, hematological and respiratory diseases, inflammation, liver diseases, cancer and human immunodeficiency virus (HIV) infection. The company sells its products through subsidiaries and distributors in Europe, the Americas, Asia-Pacific, the Middle East and Africa. It has manufacturing facilities in Edmonton, Alberta, Canada; Foster City, San Dimas, Oceanside, California; and Cork, Ireland among others. The company has partnerships with universities, medical research institutions and global pharmaceutical leaders to develop new drugs. Gilead is headquartered in Foster City, California, the US.

The company reported revenues of (US Dollars) US$27,305 million for the fiscal year ended December 2021 (FY2021), an increase of 10.6% over FY2020. In FY2021, the company’s operating margin was 36.3%, compared to an operating margin of 16.5% in FY2020. In FY2021, the company recorded a net margin of 22.8%, compared to a net margin of 0.5% in FY2020. The company reported revenues of US$7,042 million for the third quarter ended September 2022, an increase of 12.5% over the previous quarter.

Quick View – (Sofosbuvir + velpatasvir)

Report Segments
  • Innovator (NME)
Drug Name
  • (Sofosbuvir + velpatasvir)
Administration Pathway
  • Oral
Therapeutic Areas
  • Infectious Disease
Key Companies
Highest Development Stage
  • Marketed


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.